Vertex Cash from 2010 to 2024

VRTX Stock  USD 468.13  3.57  0.77%   
Vertex Pharmaceuticals Cash yearly trend continues to be fairly stable with very little volatility. Cash is likely to outpace its year average in 2024. Cash is the total amount of money in the form of currency that Vertex Pharmaceuticals has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
1990-12-31
Previous Quarter
4.6 B
Current Value
5.2 B
Quarterly Volatility
2.7 B
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Cash Growth Pattern

Below is the plot of the Cash of Vertex Pharmaceuticals over the last few years. Cash refers to the most liquid asset of Vertex Pharmaceuticals, which is listed under current asset account on Vertex Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Vertex Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Vertex Pharmaceuticals account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Vertex Pharmaceuticals' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Vertex Cash Regression Statistics

Arithmetic Mean3,735,407,200
Geometric Mean1,425,601,492
Coefficient Of Variation108.90
Mean Deviation3,448,907,467
Median1,665,412,000
Standard Deviation4,067,996,493
Sample Variance16548595.5T
Range10.9B
R-Value0.91
Mean Square Error2924331.1T
R-Squared0.84
Slope831,659,339
Total Sum of Squares231680336.5T

Vertex Cash History

202410.9 B
202310.4 B
202210.5 B
20216.8 B
2020B
20193.1 B
20182.7 B

Other Fundumenentals of Vertex Pharmaceuticals

Vertex Pharmaceuticals Cash component correlations

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash10.4 B10.9 B
Cash And Short Term Investments11.2 B11.8 B
Change In Cash-139.7 M-132.7 M
Free Cash Flow3.3 B3.4 B
Begin Period Cash Flow10.5 B11 B
Other Cashflows From Financing Activities134.6 M91.7 M
Total Cash From Operating Activities3.5 B3.7 B
Total Cash From Financing Activities-562.2 M-534.1 M
End Period Cash Flow10.4 B10.9 B
Other Non Cash Items-42.6 M-40.5 M
Other Cashflows From Investing Activities-309.3 M-293.9 M
Total Cashflows From Investing Activities-289 M-274.5 M
Cash And Cash Equivalents Changes4.3 B4.5 B
Cash Flows Other Operating-407.9 M-387.5 M
Free Cash Flow Yield 0.03  0.03 
Operating Cash Flow Per Share 13.73  14.41 
Free Cash Flow Per Share 12.72  13.36 
Cash Per Share 43.53  45.71 
Capex To Operating Cash Flow 0.07  0.08 
EV To Operating Cash Flow 26.94  28.29 
EV To Free Cash Flow 29.06  30.52 
Price To Operating Cash Flows Ratio 29.64  31.12 
Price To Free Cash Flows Ratio 31.98  33.58 
Cash Ratio 2.92  5.80 
Cash Conversion Cycle 165.94  174.24 
Operating Cash Flow Sales Ratio 0.36  0.38 
Free Cash Flow Operating Cash Flow Ratio 0.93  1.50 
Cash Flow Coverage Ratios 4.39  3.82 
Price Cash Flow Ratio 29.64  31.12 
Cash Flow To Debt Ratio 4.39  3.82 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.